Kaleido Biosciences has patented a method using glycan therapeutics to reduce inflammation in gastrointestinal inflammatory diseases with immune imbalances. The composition includes specific branched glycans with defined characteristics. This innovation could potentially offer new treatment options for such conditions. GlobalData’s report on Kaleido Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Kaleido Biosciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Kaleido Biosciences, Cancer treatment biomarkers was a key innovation area identified from patents. Kaleido Biosciences's grant share as of January 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.

Glycan therapeutic preparation for reducing inflammation in gastrointestinal diseases

Source: United States Patent and Trademark Office (USPTO). Credit: Kaleido Biosciences Inc

A recently granted patent (Publication Number: US11883422B2) discloses a method for reducing inflammation in gastrointestinal inflammatory diseases by administering a composition containing a glycan therapeutic preparation. The glycan therapeutic preparation includes branched glycans with specific glycan units, an average degree of branching, and a particular ratio of alpha- to beta-glycosidic bonds. This method aims to reduce inflammation in subjects with immune imbalances, potentially offering a novel approach to managing conditions like inflammatory bowel disease (IBD), ulcerative colitis (UC), graft versus host disease (GVHD), or psoriasis.

Furthermore, the method may involve the modulation of short-chain fatty acid levels, stimulation of beneficial gut bacteria growth, and modulation of biomarkers and cytokines. The composition may also include a probiotic microorganism and potentially an anti-inflammatory agent. By targeting immune imbalances, whether chronic, local, acute, or systemic, and addressing aberrant pathogenic cell growth, such as Escherichia coli, Klebsiella pneumoniae, Salmonella, Enterococcus, or Clostridium difficile cells, this method offers a comprehensive approach to managing gastrointestinal inflammatory diseases like drug-induced enteritis or colitis. Overall, this patented method presents a promising avenue for reducing inflammation and addressing immune imbalances in subjects with gastrointestinal inflammatory diseases, potentially improving their quality of life and treatment outcomes.

To know more about GlobalData’s detailed insights on Kaleido Biosciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies